
Point-of-Care Blood Ammonia Measurement Using a Gas-Phase Fuel Cell SensorAward last edited on: 3/3/22
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$229,542Award Phase
1Solicitation Topic Code
839Principal Investigator
Thomas Richard VeltmanCompany Information
Phase I
Contract Number: 1R43HL160404-01Start Date: 8/15/21 Completed: 1/31/23
Phase I year
2021Phase I Amount
$229,542Public Health Relevance Statement:
Project narrative:
Point-of-Care Blood Ammonia Measurement Using a Gas-Phase Fuel Cell Sensor Elevated blood ammonia is toxic to the brain, and if not treated within hours, can lead to permanent brain damage. The goal is to develop a device that measures ammonia in blood obtained by finger or heel stick procedure, thus addressing a critical unmet need for: (1) 20,000 children in the U.S. (700 infants born annually) with gene mutations leading to elevated blood ammonia; (2) patients seen in emergency rooms for altered mental status; and (3) 400,000 infants born annually before 37 weeks of gestation at risk due to immature liver function. The device will permit early diagnosis and prompt treatment of elevated ammonia, thus preventing brain damage in many children and improving the management and quality of life for patients with liver disease. 1
Project Terms:
Acids ; Adult ; 21+ years old ; Adult Human ; adulthood ; Ambulatory Care Facilities ; Outpatient Clinics ; Ammonia ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Blood ; Blood Reticuloendothelial System ; Blood donor ; Blood Glucose ; Blood Sugar ; Blood Volume ; Brain ; Brain Nervous System ; Encephalon ; Cells ; Cell Body ; Centrifugation ; Centrifugation Fractionation ; Child ; 0-11 years old ; Child Youth ; Children (0-21) ; youngster ; Clinical Research ; Clinical Study ; Clinical Trials ; Confidence Intervals ; Cessation of life ; Death ; Diagnosis ; Pharmaceutical Preparations ; Drugs ; Medication ; Pharmaceutic Preparations ; drug/agent ; Emergency Situation ; Emergencies ; Exhibits ; Fingers ; Fluorouracil ; 5-FU ; 5-Fluracil ; 5FU ; Fluoro Uracil ; Fluoruracil ; Fluouracil ; Gases ; Genes ; Goals ; Heel ; Hemodialysis ; Hemodialyses ; Hospitals ; Infant ; Premature Infant ; infants born premature ; infants born prematurely ; premature baby ; premature infant human ; preterm baby ; preterm infant ; preterm infant human ; Laboratories ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Liver ; hepatic body system ; hepatic organ system ; Liver Cirrhosis ; Hepatic Cirrhosis ; Liver diseases ; Hepatic Disorder ; hepatic disease ; hepatopathy ; liver disorder ; Manuals ; Inborn Errors of Metabolism ; Hereditary Metabolic Disorder ; inborn metabolism disorder ; Mutation ; Genetic Alteration ; Genetic Change ; Genetic defect ; genome mutation ; Pain ; Painful ; Paper ; Patients ; Plasma ; Blood Plasma ; Plasma Serum ; Reticuloendothelial System, Serum, Plasma ; Production ; Publishing ; Quality of life ; QOL ; Risk ; Testing ; Time ; Transportation ; Work ; Generations ; Measures ; Liver Dysfunction ; Guidelines ; Blood specimen ; Blood Sample ; detector ; Pump ; sensor ; improved ; Procedures ; Clinical ; Phase ; Evaluation ; Training ; Hyperammonemia ; liver function ; Individual ; diabetic ; Measurement ; Brain Injuries ; Acquired brain injury ; brain damage ; brain-injured ; mental state ; mental status ; fluid ; liquid ; Liquid substance ; Venous ; Intravenous ; Hour ; System ; Emergency Department ; Emergency room ; Accident and Emergency department ; early detection ; Early Diagnosis ; Gene Alteration ; Gene Mutation ; Performance ; rapid diagnosis ; aqueous ; Venipunctures ; Speed ; novel technologies ; new technology ; Devices ; Sampling ; performance tests ; portability ; Cannulations ; µfluidic ; Microfluidics ; preventing ; prevent ; Address ; Data ; Detection ; Cancer Patient ; Collection ; Monitor ; Process ; Development ; developmental ; point of care ; design ; designing ; Population ; Trauma ; chemotherapy ; trial comparing ; commercialization ; nonalcoholic steatohepatitis ; NASH ; non-alcohol induced steatohepatitis ; non-alcoholic steato-hepatitis ; non-alcoholic steatohepatitis ; nonalcoholic steato-hepatitis ; 37 weeks gestation ; 37 weeks completed gestation ; Child Health ; adult obesity ; adult adiposity ; adults with obesity ; Home ; point of care
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00